Last reviewed · How we verify

local intracoronary dosis of Paclitaxel

University Hospital Tuebingen · Phase 3 active Small molecule

local intracoronary dosis of Paclitaxel is a Taxane Small molecule drug developed by University Hospital Tuebingen. It is currently in Phase 3 development for Coronary in-stent restenosis.

Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying.

Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying. Used for Coronary in-stent restenosis.

At a glance

Generic namelocal intracoronary dosis of Paclitaxel
SponsorUniversity Hospital Tuebingen
Drug classTaxane
TargetMicrotubules
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Paclitaxel binds to tubulin, a protein that makes up microtubules, and prevents them from disassembling. This leads to the accumulation of stable microtubules, which in turn prevents the cell from entering the mitotic phase of cell division. As a result, cancer cells are unable to multiply and eventually die.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about local intracoronary dosis of Paclitaxel

What is local intracoronary dosis of Paclitaxel?

local intracoronary dosis of Paclitaxel is a Taxane drug developed by University Hospital Tuebingen, indicated for Coronary in-stent restenosis.

How does local intracoronary dosis of Paclitaxel work?

Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying.

What is local intracoronary dosis of Paclitaxel used for?

local intracoronary dosis of Paclitaxel is indicated for Coronary in-stent restenosis.

Who makes local intracoronary dosis of Paclitaxel?

local intracoronary dosis of Paclitaxel is developed by University Hospital Tuebingen (see full University Hospital Tuebingen pipeline at /company/university-hospital-tuebingen).

What drug class is local intracoronary dosis of Paclitaxel in?

local intracoronary dosis of Paclitaxel belongs to the Taxane class. See all Taxane drugs at /class/taxane.

What development phase is local intracoronary dosis of Paclitaxel in?

local intracoronary dosis of Paclitaxel is in Phase 3.

What are the side effects of local intracoronary dosis of Paclitaxel?

Common side effects of local intracoronary dosis of Paclitaxel include Myelosuppression, Neutropenia, Anemia, Thrombocytopenia.

What does local intracoronary dosis of Paclitaxel target?

local intracoronary dosis of Paclitaxel targets Microtubules and is a Taxane.

Related